Scotti et al reported the CITE score for evaluating a patient with mitral valve regurgitation who is COAPT-ineligible. This can help to identify a patient undergoing transcatheter edge-to-edge repair (TEET). The authors are from multiple institutions in Italy
COPAT is an acronym for a clinical trial (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation).
CITE is an acronym for COAPT-ineligible patient who underwent TEER.
Patient selection: mitral valve regurgitation, COAPT-ineligible patient who underwent TEER (transcatheter edge-to-edge repair)
Parameters:
(1) left ventricular impairment
(2) hemodynamic instability
(3) NYHA class
(4) peripheral arterial disease
(5) hemoglobin in g/dL, from 7 to 17
(6) atrial fibrillation
(7) serum BNP in pg/mL, from 0 to 2,000
line for hemoglobin =
= 14.286 - (0.84 * (hemoglobin))
line for serum BNP =
= (0.005 * (BNP))
|
Parameter
|
Finding
|
Points
|
|
left ventricular impairment
|
no
|
0
|
|
|
yes
|
3.32
|
|
hemodynamic instability
|
no
|
0
|
|
|
yes
|
2.52
|
|
NYHA class
|
I or II
|
0
|
|
|
III or IV
|
3.12
|
|
peripheral arterial disease
|
no
|
0
|
|
|
yes
|
2.17
|
|
atrial fibrillation
|
no
|
0
|
|
|
yes
|
1.45
|
total score =
= SUM(points for all of the parameters)
Interpretation:
• minimum score: 0
• maximum score: 27.69
value of X =
= (-0.005807 * ((score)^2)) - (0.1289 * (score)) + 2.309
probability of 2-year freedom from death or heart failure hospitalization =
= 1 / (1 + EXP((-1) * X))
